You are here

AIRWAY PERFUSION ASSISTED LIQUID VENTILATOR

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: PHS2001-2
Agency Tracking Number: 2R42HL057040-02
Amount: $0.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
20268 SKYPARK DR REDDING, CA 96002
REDDING, CA 96002
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JAMES PARKER
 (334) 460-6826
 JPARKER@USOUTHAL.EDU
Business Contact
 PEARSON, ROBERT M.
Phone: (530) 226-0727
Research Institution
 UNIVERSITY OF SOUTH ALABAMA
 
UNIVERSITY OF SOUTH ALABAMA
MOBILE, AL 36688
United States

 Nonprofit College or University
Abstract

DESCRIPTION (provided by applicant): We have developed and patented (U.S. Pat
No. 5,706,830) a new type of closed circuit perfluorocarbon (PFC) liquid
ventilator with enhanced capabilities for gas exchange and exudates clearance
from the lungs. This system has potential application to rescue of patients in
acute respiratory failure and treatment of cystic fibrosis. The system employs
a continuous isovolumetric perfusion (bias flow) of oxygenated PFC through one
lumen of a double lumen endotracheal catheter that is superimposed on tidal
liquid ventilation (liv). Phase I studies in newborn piglets indicate that bias
flow significantly improved blood gases and increased the clearance of a five
percent albumin solution from the lung by over 3-fold. During Phase II we
propose to finalize the prototype design and control system software for
ventilatory parameters and a feedback control of lung liquid volume based on
measurements of end-expiratory stop-flow pressures. High performance pulseless
pumps, an oxygenator and vapor recovery system will be included as well as
protective algorithms and relief valves to limit airway pressure excursions.
Phase II experimental studies in piglets and rabbits will examine novel
applications of TLV with bias flow for sustaining arterial blood gases during
oleic acid lung injury, increasing the clearance rate of five percent albumin
solution and mucus-like gels from the lung, and enhancing the homogeneity of
gene expression for a reporter gene introduced during TLV. We will also apply
for an Investigational Device Exemption (IDE) from the Food and Drug
Administration during Phase II to distribute ventilator prototypes to research
institutions.

PROPOSED COMMERCIAL APPLICATION:
This liquid ventilator will be used in infant and adult intensive care units to treat end-stage respiratory failure as a lower cost alternative to extracorporeal oxygenation. Other applications include continuous intrapulmonary administration of drugs and anesthetics and clearance of material from the lungs.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government